S1PR3 and Alzheimer disease: Reduced mRNA for S1PR1 and upregulated S1PR3 we previously observed in AD brains might lead to changes in the G protein–mediated regulation of genes engaged in sphingolipid metabolism and signaling [10, 11, 27]), Thus, altered S1PR1 may change fingolimod’s effects in the Alzheimer’s brain.